Tirzepatide at a Med Spa or Weight Loss Clinic: What It Is, Cost and Who Prescribes

Tirzepatide is an injectable medicine injected once weekly.

Drug maker Eli Lilly sells the same molecule under two brand names, Zepbound and Mounjaro, and the two brands carry different approvals.

The Zepbound label approves it, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition.

Zepbound is also approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Mounjaro is the same molecule with a different label: it is approved for type 2 diabetes, to improve glycemic control in adults and children 10 and older and to reduce cardiovascular risk.

It is not approved as a weight-loss product.

Zepbound is supplied as single-dose pens and single-dose vials and, following a January 2026 label change, also as multi-dose vials and a 4-dose single-patient-use KwikPen.

The label says never share a KwikPen between patients, even with a new needle.

The labeled dosing starts at 2.5 mg once weekly for 4 weeks, and the label calls 2.5 mg a starter dose only, not a maintenance dose.

The next step is 5 mg, with increases in 2.5 mg steps after at least 4 weeks on each dose.

Labeled maintenance doses for weight reduction are 5 mg, 10 mg or 15 mg once weekly; obstructive sleep apnea treatment uses 10 mg or 15 mg, and 15 mg once weekly is the maximum for all indications.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist: one molecule that acts on both of those receptors. Semaglutide, the medicine in Wegovy and Ozempic, acts on the GLP-1 receptor only.

The brand names track the labels.

Wegovy is the semaglutide brand approved for weight reduction and maintenance, and Ozempic is approved for type 2 diabetes rather than weight loss.

Zepbound and Mounjaro are both tirzepatide: Zepbound for weight reduction and moderate to severe obstructive sleep apnea, Mounjaro for type 2 diabetes.

One warning the two drugs share: the Wegovy label, like Zepbound's, carries a boxed warning for thyroid C-cell tumors, and both drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

What the dual action means for any one person is not something the trial averages answer.

Each trial carries its own population, doses and measurement window, so the percentages are not directly comparable, and a mean from one trial is not a prediction for an individual.

A licensed prescriber can compare semaglutide and tirzepatide against a specific patient's history.

Weight loss clinics, med spas and telehealth companies sell tirzepatide in medical weight loss programs, and "tirzepatide" can mean different things at each: the brand-name drug, a compounded copy made by a pharmacy, or a program built around one of the two.

Which product a program dispenses is the first thing to ask.

The backdrop to compounded copies is the shortage years: tirzepatide had been in shortage since 2022, and the FDA declared the injection shortage resolved on October 2, 2024, re-evaluated the decision during litigation and reaffirmed it on December 19, 2024.

With both GLP-1 shortages resolved, the FDA's grace periods for compounders ended by May 22, 2025.

What remains is limited.

Under the rules for 503A pharmacies, a compounded copy with the same active ingredient, in a similar strength and given the same way as the approved drug, is treated as an "essentially copy" unless the prescriber documents that a specific change makes a significant clinical difference for an identified patient.

The FDA has said it does not intend to act against a 503A pharmacy that fills four or fewer prescriptions of such a product in a calendar month.

A compounded drug is not FDA-approved.

The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and it says they should be used only in patients whose medical needs cannot be met by an FDA-approved drug.

The FDA also lists "claims such as the compounded drug is the same as an FDA-approved drug" among the red flags of a seller to avoid.

A program that markets its compounded product as "the same as" Zepbound is using that red-flag wording word for word.

The results that can be quoted come from fixed-length trials, not from clinic before-and-after photos.

The numbers below are trial means at set checkpoints, which is not the same as a forecast for any one patient.

In SURMOUNT-1, a trial of 2,539 adults with obesity or overweight and no diabetes, the mean weight change at 72 weeks was -15.0% on the 5 mg dose, -19.5% on 10 mg and -20.9% on 15 mg, against -3.1% on placebo.

In the same trial, 50% of participants on 10 mg and 57% on 15 mg lost 20% or more of their body weight at 72 weeks, versus 3% on placebo, and 85–91% lost at least 5%.

Results were smaller in people with type 2 diabetes.

In SURMOUNT-2, mean weight change at 72 weeks was -12.8% on 10 mg and -14.7% on 15 mg, against -3.2% on placebo.

What happens after stopping has been measured too.

In SURMOUNT-4, after 36 weeks of tirzepatide with a mean loss of 20.9%, participants switched to placebo regained 14.0% of body weight between week 36 and week 88, while those who stayed on the drug lost a further 5.5%.

Measured from the starting weight, the group that stayed on the drug ended week 88 at -25.3% and the placebo group at -9.9%.

Keep the scope of those numbers.

They are trial means at fixed checkpoints (week 72, or week 88 in SURMOUNT-4) with structured lifestyle counseling alongside the drug, and the biggest numbers come from the top doses.

We could not find month-by-month weight-loss figures in quotable text in the label or the trial reports: the label shows the time course only in its charts, and the figures stated in text are checkpoint means such as week 72.

In the trials, weight loss built up gradually while the dose was stepped up.

In the Zepbound label's pooled weight trials, nausea occurred in 25–29% of Zepbound patients depending on dose, against 8% on placebo; diarrhea in 19–23% versus 8%; vomiting in 8–13% versus 2%; and constipation in 11–17% versus 5%.

Overall, 56% of Zepbound patients reported gastrointestinal side effects versus 30% on placebo, and most of the nausea, vomiting and diarrhea showed up during dose escalation and decreased over time.

Hair loss was reported in 4–5% of Zepbound patients versus 1% on placebo in the weight-reduction trials.

Side effects are also the reason some participants stop: in those pooled trials, 4.8% on 5 mg, 6.3% on 10 mg and 6.7% on 15 mg stopped permanently because of adverse reactions, versus 3.4% on placebo — mostly in the first few months, and mostly from gastrointestinal effects.

The label's warning list goes beyond the digestive tract.

It includes:

• severe gastrointestinal reactions — Zepbound is not recommended in severe gastroparesis;
• acute kidney injury from dehydration;
• gallbladder disease (gallstones in 1.1% of Zepbound patients versus 1% on placebo; gallbladder inflammation 0.7% versus 0.2%);
• acute pancreatitis;
• serious allergic reactions;
• low blood sugar when used with insulin or sulfonylurea medicines;
• diabetic retinopathy complications;
• pulmonary aspiration under anesthesia or deep sedation.

One warning is specific to contraception.

Zepbound may reduce the effectiveness of oral birth control, so the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase, and stopping the drug when pregnancy is recognized.

How any of this applies to one person is a question for the prescribing clinician.

There are two price layers here: what the drug itself costs, and what a clinic charges for the program wrapped around it.

The drug layer is the one with published numbers.

Eli Lilly publishes self-pay prices for Zepbound on its own site: as of October 16, 2026, a 1-month (28-day) supply of the single-patient-use KwikPen cost $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg and $699 at 10, 12.5 and 15 mg, and the same $299 starting price applies to 4 vials.

Lilly also lists a $449 purchase offer for 7.5 mg to 15 mg when each refill is bought within 45 days of the previous one.

These are Lilly's own prices, dated to the day we read them, and its terms can change.

The starting price has fine print.

Lilly says $299 applies to the KwikPen or the vials, not to the Zepbound single-dose pen, and that with commercial insurance which does not cover Zepbound, the single-dose pen can cost as low as $499 per month with its savings card.

What a med spa or weight loss clinic charges for a tirzepatide program is a separate number, and we could not confirm program prices from the sources we read.

A clinic quote is worth unpacking line by line: which product it covers, at which dose, for how many months, and what visits or labs are included.

Within Lilly's published list, the monthly figure rises with the dose, from $299 at 2.5 mg to $699 at 15 mg, and the formulation matters too, because the single-dose pen is priced separately from the KwikPen and the vials.

Insurance coverage and savings offers change what a patient actually pays.

Zepbound is prescription-only: it needs a valid prescription from a licensed prescriber, and the FDA tells patients to obtain that prescription and fill it at a state-licensed pharmacy.

For a med spa or weight loss clinic, that means the program has to be built around a prescriber and a pharmacy: the drug reaches the patient the way the FDA describes, on a prescriber's prescription, filled at a state-licensed pharmacy.

Who the prescriber can be depends on the state and on the prescriber's license.

For nurse practitioners, the American Association of Nurse Practitioners groups the states three ways: Full Practice states, where a nurse practitioner may evaluate, diagnose and prescribe under the board of nursing alone; Reduced Practice states, where state law requires a career-long collaborative agreement with another health provider for at least one element of care; and Restricted Practice states, where career-long supervision, delegation or team management is required.

Because those categories are set state by state, it is a fair question to ask any clinic who writes its tirzepatide prescriptions and what the supervision arrangements are where you live.

Because Zepbound is prescription-only, a "tirzepatide clinic" is really a clinic plus a prescriber plus a pharmacy, and comparing programs means comparing all three.

The FDA's red-flag list for GLP-1 sellers is a practical place to start.

FDA tells patients to watch for a seller that claims a compounded drug is the same as an FDA-approved drug, offers discounts that seem too good to be true, prescribes without screening by a licensed doctor, has no doctor available for questions, shows label spelling errors or a wrong pharmacy address, or has a pharmacy name that seems fraudulent.

For telehealth programs versus in-person clinics, see tirzepatide online vs in a clinic.

Those red flags translate into questions any program should answer before you pay:

The dosing questions matter beyond marketing.

The label's schedule starts at 2.5 mg weekly for 4 weeks and steps up no sooner than 4 weeks apart, so a program that starts higher or escalates faster is outside the labeled schedule.

Comparing a few programs near you against the questions above, before committing to months of weekly injections, is the practical version of shopping for tirzepatide.